Kymab announced today the appointment of Anne Hyland as Chief Financial Officer, with effect from 1 March 2015.
Anne has a strong track record within the biopharma sector, bringing with her over 25 years of financial experience with both public and private companies. Most recently, Anne served as Chief Financial Officer of BBI Diagnostics Group Ltd and FTSE listed Vectura Group plc (LSE: VEC).
"I am very pleased to welcome Anne to Kymab’s senior management team," commented Dr David Chiswell, Chairman and interim CEO of Kymab. "Anne is an experienced CFO with a successful track record of creating value and growth for both public and private companies. Anne’s strong skill set will be invaluable as we build Kymab into a substantial global biopharmaceutical company.”
Anne currently serves as Non-executive Director and Chair of the Audit Committee of the FTSE-250 global specialty chemicals company, Elementis plc (LSE:ELM). Prior to Vectura, Anne held a number of senior finance position, including Director of Corporate Finance at the then FTSE 100 Celltech Group plc, Medeva plc and KPMG.
"I am delighted to join Kymab at this exciting time," commented newly appointed Chief Financial Officer Anne Hyland. "The significant level of investment the company and management team has attracted is impressive. Kymab is a company with tremendous capabilities and talented people and I look forward to helping build further growth and value."
Anne is a Chartered Accountant (FCA), a Corporate Tax Adviser (CTA – AITI) and holds a degree in Business studies from Trinity College, Dublin. She is also a Trustee/Director of Sustrans, the charity that has created the National Cycle Network. Anne has been one of the Cranfield University Female FTSE 100 Women to Watch since 2009.
Kymab and Kymouse are trademarks of Kymab Limited.